Hepatitis B precore protein: Pathogenic potential and therapeutic promise

Yonsei Medical Journal

Volumn 53, Issue 5, 2012, Pages 875-885

  Walsh, Renae ^a   Locarnini, Stephen ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

Chronic hepatitis B; Hepatitis B e antigen; Intrabody; Precore protein

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS X PROTEIN; HEPATITIS B(E) ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PEGINTERFERON ALPHA; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIBODY TITER; CANCER RISK; CD4+ T LYMPHOCYTE; DISEASE COURSE; DRUG COST; DRUG MECHANISM; ENDEMIC DISEASE; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS B VIRUS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MOLECULAR PATHOLOGY; MORTALITY; NONHUMAN; OPEN READING FRAME; REVIEW; SEROCONVERSION; VIRION; VIROLOGY; VIRUS GENOME; VIRUS IMMUNITY; VIRUS REPLICATION; VIRUS TRANSMISSION;

HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS;

EID: 84864583849     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2012.53.5.875     Document Type: Review

References (73)

1. Kane MA. Global status of hepatitis B immunisation. Lancet 1996;348:6.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107.
3. Kim BK, Revill PA, Ahn SH. HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther 2011;16:1169-86.
4. Lai CL, Yuen MF. The natural history of chronic hepatitis B. J Viral Hepat 2007;14 Suppl 1:6-10.
5. McMahon BJ. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int 2009;3:334-42.
6. Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 2003;38:1075-86.
7. Chang C, Enders G, Sprengel R, Peters N, Varmus HE, Ganem D. Expression of the precore region of an avian hepatitis B virus is not required for viral replication. J Virol 1987;61:3322-5.
8. Chen MT, Billaud JN, Sällberg M, Guidotti LG, Chisari FV, Jones J, et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci U S A 2004;101:14913-8.
9. Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci U S A 1990;87: 6599-603.
10. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45: 507-39.
11. Ou JH. Molecular biology of hepatitis B virus e antigen. J Gastroenterol Hepatol 1997;12:S178-87.
12. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol 2011;26 Suppl 1:123-30.
13. Kao JH. Molecular epidemiology of hepatitis B virus. Korean J Intern Med 2011;26:255-61.
14. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-74.
15. Visvanathan K, Skinner NA, Thompson AJ, Riordan SM, Sozzi V, Edwards R, et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007;45: 102-10.
16. Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut 2012;61 Suppl 1:i6-17.
17. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009;49(5 Suppl):S45-55.
18. Herkel J, Carambia A. Let it B in viral hepatitis? J Hepatol 2011; 55:5-7.
19. Creagh EM, O'Neill LA. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 2006;27:352-7.
20. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999;18:6853-66.
21. Thompson AJ, Locarnini SA. Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response. Immunol Cell Biol 2007;85:435-45.
22. Roy CR, Mocarski ES. Pathogen subversion of cell-intrinsic innate immunity. Nat Immunol 2007;8:1179-87.
23. Chen Z, Cheng Y, Xu Y, Liao J, Zhang X, Hu Y, et al. Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol 2008;128:400-8.
24. Lang T, Lo C, Skinner N, Locarnini S, Visvanathan K, Mansell A. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol 2011; 55:762-9.
25. Riordan SM, Skinner N, Kurtovic J, Locarnini S, Visvanathan K. Reduced expression of toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B. Clin Vaccine Immunol 2006;13:972-4.
26. Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009;49:1132-40.
27. Revill P, Yuen L, Walsh R, Perrault M, Locarnini S, Kramvis A. Bioinformatic analysis of the hepadnavirus e-antigen and its precursor identifies remarkable sequence conservation in all orthohepadnaviruses. J Med Virol 2010;82:104-15.
28. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008;453:667-71.
29. Han SH, Martin P, Edelstein M, Hu R, Kunder G, Holt C, et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003;9:182-7.
30. Neumann AU, Phillips S, Levine I, Ijaz S, Dahari H, Eren R, et al. Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells. Hepatology 2010;52:875-85.
31. Schilling R, Ijaz S, Davidoff M, Lee JY, Locarnini S, Williams R, et al. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol 2003;77:8882-92.
32. Maruyama T, McLachlan A, Iino S, Koike K, Kurokawa K, Milich DR. The serology of chronic hepatitis B infection revisited. J Clin Invest 1993;91:2586-95.
33. Chen M, Sällberg M, Hughes J, Jones J, Guidotti LG, Chisari FV, et al. Immune tolerance split between hepatitis B virus precore and core proteins. J Virol 2005;79:3016-27.
34. Milich DR, Chen MK, Hughes JL, Jones JE. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol 1998;160: 2013-21.
35. Walsh R, Nuttall S, Revill P, Colledge D, Cabuang L, Soppe S, et al. Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody. Virology 2011;411:132-41.
36. Dienes HP, Gerken G, Goergen B, Heermann K, Gerlich W, Meyer zum Büschenfelde KH. Analysis of the precore DNA sequence and detection of precore antigen in liver specimens from patients with anti-hepatitis B e-positive chronic hepatitis. Hepatology 1995;21:1-7.
37. Kimura T, Ohno N, Terada N, Rokuhara A, Matsumoto A, Yagi S, et al. Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain. J Biol Chem 2005;280:21713-9.
38. Messageot F, Salhi S, Eon P, Rossignol JM. Proteolytic processing of the hepatitis B virus e antigen precursor. Cleavage at two furin consensus sequences. J Biol Chem 2003;278:891-5.
39. Takahashi K, Machida A, Funatsu G, Nomura M, Usuda S, Aoyagi S, et al. Immunochemical structure of hepatitis B e antigen in the serum. J Immunol 1983;130:2903-7.
40. Takahashi K, Brotman B, Usuda S, Mishiro S, Prince AM. Full-genome sequence analyses of hepatitis B virus (HBV) strains recovered from chimpanzees infected in the wild: implications for an origin of HBV. Virology 2000;267:58-64.
41. Watts NR, Conway JF, Cheng N, Stahl SJ, Steven AC, Wingfield PT. Role of the propeptide in controlling conformation and assembly state of hepatitis B virus e-antigen. J Mol Biol 2011;409:202-13.
42. Steven AC, Conway JF, Cheng N, Watts NR, Belnap DM, Harris A, et al. Structure, assembly, and antigenicity of hepatitis B virus capsid proteins. Adv Virus Res 2005;64:125-64.
43. Chen RY, Edwards R, Shaw T, Colledge D, Delaney WE 4th, Isom H, et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003;37:27-35.
44. Lamberts C, Nassal M, Velhagen I, Zentgraf H, Schröder CH. Precore-mediated inhibition of hepatitis B virus progeny DNA synthesis. J Virol 1993;67:3756-62.
45. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989;2:588-91.
46. Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996;70:5845-51.
47. Scaglioni PP, Melegari M, Wands JR. Posttranscriptional regulation of hepatitis B virus replication by the precore protein. J Virol 1997;71:345-53.
48. Locarnini S, Shaw T, Dean J, Colledge D, Thompson A, Li K, et al. Cellular response to conditional expression of the hepatitis B virus precore and core proteins in cultured hepatoma (Huh-7) cells. J Clin Virol 2005;32:113-21.
49. Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006;44:422-31.
50. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008;48:88-98.
51. Yuen L, Ayers A, Littlejohn M, Edwards R, Locarnini S. Evolution of the hepatitis B surface antigen in European and Asian HBV genotypes during the era of antiviral therapy. Hepatol Int 2011: 5:3-558 (Abstract PP05-159).
52. Lever A, Waters J, Brook G, Karayiannis P, Thomas H. Treatment of chronic hepatitis B virus infection with monoclonal antibody to the hepatitis B virus surface antigen in two patients with hypogammaglobulinaemia. In: Zuckerman AJ, editor. Viral Hep & Liver Dis. New York: Alan R Liss Inc; 1987. p.961-2.
53. Lever AM, Waters J, Brook MG, Karayiannis P, Thomas HC. Monoclonal antibody to HBsAg for chronic hepatitis B virus infection with hypogammaglobulinaemia. Lancet 1990;335:1529.
54. Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008;47:428-34.
55. National Institutes of Health. RFA-DK-07-011. Hepatitis B clinical research network. http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-07-011.html, Released: December 2007.
56. Nuttall SD, Krishnan UV, Doughty L, Pearson K, Ryan MT, Hoogenraad NJ, et al. Isolation and characterization of an IgNAR variable domain specific for the human mitochondrial translocase receptor Tom70. Eur J Biochem 2003;270:3543-54.
57. Roux KH, Greenberg AS, Greene L, Strelets L, Avila D, McKinney EC, et al. Structural analysis of the nurse shark (new) antigen receptor (NAR): molecular convergence of NAR and unusual mammalian immunoglobulins. Proc Natl Acad Sci U S A 1998;95: 11804-9.
58. Ewert S, Cambillau C, Conrath K, Plückthun A. Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains. Biochemistry 2002;41:3628-36.
59. Nuttall SD, Humberstone KS, Krishnan UV, Carmichael JA, Doughty L, Hattarki M, et al. Selection and affinity maturation of IgNAR variable domains targeting Plasmodium falciparum AMA1. Proteins 2004;55:187-97.
60. Stanfield RL, Dooley H, Flajnik MF, Wilson IA. Crystal structure of a shark single-domain antibody V region in complex with lysozyme. Science 2004;305:1770-3.
61. Streltsov VA, Varghese JN, Carmichael JA, Irving RA, Hudson PJ, Nuttall SD. Structural evidence for evolution of shark Ig new antigen receptor variable domain antibodies from a cell-surface receptor. Proc Natl Acad Sci U S A 2004;101:12444-9.
62. Streltsov VA, Carmichael JA, Nuttall SD. Structure of a shark IgNAR antibody variable domain and modeling of an early-developmental isotype. Protein Sci 2005;14:2901-9.
63. Dandri M, Volz TK, Lütgehetmann M, Petersen J. Animal models for the study of HBV replication and its variants. J Clin Virol 2005;34 Suppl 1:S54-62.
64. Ladner SK, Otto MJ, Barker CS, Zaifert K, Wang GH, Guo JT, et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother 1997;41:1715-20.
65. Sells MA, Chen ML, Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A 1987;84:1005-9.
66. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5:215-29.
67. Eren R, Lubin I, Terkieltaub D, Ben-Moshe O, Zauberman A, Uhlmann R, et al. Human monoclonal antibodies specific to hepatitis B virus generated in a human/mouse radiation chimera: the Trimera system. Immunology 1998;93:154-61.
68. Eren R, Ilan E, Nussbaum O, Lubin I, Terkieltaub D, Arazi Y, et al. Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees. Hepatology 2000;32: 588-96.
69. Ilan E, Burakova T, Dagan S, Nussbaum O, Lubin I, Eren R, et al. The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents. Hepatology 1999;29:553-62.
70. Dandri M, Burda MR, Török E, Pollok JM, Iwanska A, Sommer G, et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 2001;33:981-8.
71. Walter E, Keist R, Niederöst B, Pult I, Blum HE. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. Hepatology 1996;24:1-5.
72. Menne S, Cote PJ. The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J Gastroenterol 2007;13:104-24.
73. Hamatake RK, Lau JYN. Methods in Molecular Medicine. vol 96: Hepatitis B and D Protocols, vol 2. Humana Press; 2004.